OMERO
LIVE

Serial Number

79315257

Owner

Glencoe Software Inc.

Attorney

Stacey J. Watson, Esq.

Filing Date

Mar 9, 2021

Add to watchlist:

No watchlists yet
View on USPTO

OMERO Trademark

Serial Number: 79315257 • Registration: 7497630

OMERO is a trademark filed by Glencoe Software Inc. on March 9, 2021. The trademark is classified under Class 9 (Computers & Electronics), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Glencoe Software Inc. (13 trademarks)

800 5th Avenue #101-259

Entity Type: 03

Trademark Details

Filing Date

March 9, 2021

Registration Date

September 10, 2024

Published for Opposition

November 1, 2022

Goods & Services

Computer software that is downloaded and installed for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; computer software downloadable from the Internet for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science;data access and data management software tools that are downloaded and installed for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; downloadable electronic publications in the nature of scientific journals, periodicals and newsletters relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof

Business services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science, namely, management of biological and biomedical data and images for business enterprises; data processing services relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof

Licensing of computer software for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof

Design and development of computer software, data access and data management software tools for use in connection with the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; computer programming; installation, maintenance and repair of computer software; design of computer websites and maintenance thereof, all relating to the accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; software as a service (SAAS) featuring software for accessing, visualisation, analysis, management, publication, sharing, storage and manipulation of biological and biomedical data and images in the field of healthcare, life science and biomedical science; information, advisory and consultancy services in connection with the aforesaid services; none of the foregoing for use by clinical care providers, future or current patients, or their families in connection with pharmaceuticals, biopharmaceuticals or therapeutic methods, or produced, designed, or marketed for providing medical and scientific research summaries, reports, or opinions regarding the efficacy, safety, pharmacological characteristics, or other properties of pharmaceutical and biopharmaceutical products, product candidates, development programs, therapeutic methods, drug delivery systems, medical treatments, or diagnostic methods, and relating to a specific disease, disorder, or category thereof

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
May 9, 2025 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 18, 2025 FICS
FINAL DISPOSITION PROCESSED
Apr 18, 2025 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 10, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 10, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 10, 2024 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Aug 2, 2024 TMBN
OPPOSITION TERMINATED NO. 999999
Aug 2, 2024 OP.T
OPPOSITION DISMISSED NO. 999999
Aug 2, 2024 OP.D
REFUSAL PROCESSED BY IB
May 30, 2023 RFNT
OPPOSITION INSTITUTED NO. 999999
May 3, 2023 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
May 1, 2023 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Apr 29, 2023 OPNC
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 3, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 14, 2022 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 14, 2022 OPNR
EXTENSION OF TIME TO OPPOSE RECEIVED
Nov 14, 2022 ETOF
NOTIFICATION PROCESSED BY IB
Nov 1, 2022 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 1, 2022 NPUB
PUBLISHED FOR OPPOSITION
Nov 1, 2022 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 12, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Oct 12, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 12, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 23, 2022 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2022 CRFA
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 23, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 23, 2022 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Sep 22, 2022 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
May 11, 2022 GNFN
FINAL REFUSAL E-MAILED
May 11, 2022 GNFR
FINAL REFUSAL WRITTEN
May 11, 2022 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
May 9, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 8, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 8, 2022 TROA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 5, 2022 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 5, 2022 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 5, 2022 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 5, 2022 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 5, 2022 COAR
REFUSAL PROCESSED BY IB
Nov 29, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Nov 9, 2021 RFCS
REFUSAL PROCESSED BY MPU
Nov 8, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Oct 8, 2021 RFCR
NON-FINAL ACTION WRITTEN
Oct 7, 2021 CNRT
ASSIGNED TO EXAMINER
Oct 4, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jul 30, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 26, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jul 19, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 8, 2021 REPR